{"id":144,"date":"2025-06-04T10:00:00","date_gmt":"2025-06-04T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=144"},"modified":"2025-09-02T07:45:36","modified_gmt":"2025-09-02T07:45:36","slug":"china-bd-2025-intragrand-and-transpire-enters-a-license-on-pde4-inhibitor-itg-1052","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/144.html","title":{"rendered":"[China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-06-03 (June 3, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: ITG-1052 (Lenamilast)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Suzhou Intragrand Pharma (China) <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Transpire Bio Inc.\uff08US\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Small &nbsp;Molecule, inhaled<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: PDE4 inhibitor<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: idiopathic pulmonary fibrosis and other indications<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Preclinical<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Intragrand has granted Transpire Bio an exclusive license to develop, manufacture, and commercialize ITG-1052 in all territories except China. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Terms of the agreement are not disclosed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.transpirebio.com\/transpire-bio-announces-rd-and-manufacturing-expansion\/\">Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor \u2013 Transpire Bio<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-06-03 (June 3, 2025) Asset Name: ITG-1052 (Lenamilast) Licensor: Suzhou Intragrand Pharma (China) Licensee &hellip; <a title=\"[China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/144.html\"><span class=\"screen-reader-text\">[China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-144","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=144"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/144\/revisions"}],"predecessor-version":[{"id":147,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/144\/revisions\/147"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}